247 related articles for article (PubMed ID: 24961753)
1. Effects of the cholesteryl ester transfer protein inhibitor evacetrapib on lipoproteins, apolipoproteins and 24-h ambulatory blood pressure in healthy adults.
Suico JG; Wang MD; Friedrich S; Cannady EA; Konkoy CS; Ruotolo G; Krueger KA
J Pharm Pharmacol; 2014 Nov; 66(11):1576-85. PubMed ID: 24961753
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, safety, tolerability, and pharmacokinetic profile of evacetrapib administered as monotherapy or in combination with atorvastatin in Japanese patients with dyslipidemia.
Teramoto T; Takeuchi M; Morisaki Y; Ruotolo G; Krueger KA
Am J Cardiol; 2014 Jun; 113(12):2021-9. PubMed ID: 24786356
[TBL] [Abstract][Full Text] [Related]
3. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.
Nicholls SJ; Brewer HB; Kastelein JJ; Krueger KA; Wang MD; Shao M; Hu B; McErlean E; Nissen SE
JAMA; 2011 Nov; 306(19):2099-109. PubMed ID: 22089718
[TBL] [Abstract][Full Text] [Related]
4. Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure.
Cao G; Beyer TP; Zhang Y; Schmidt RJ; Chen YQ; Cockerham SL; Zimmerman KM; Karathanasis SK; Cannady EA; Fields T; Mantlo NB
J Lipid Res; 2011 Dec; 52(12):2169-2176. PubMed ID: 21957197
[TBL] [Abstract][Full Text] [Related]
5. Anacetrapib, but not evacetrapib, impairs endothelial function in CETP-transgenic mice in spite of marked HDL-C increase.
Simic B; Mocharla P; Crucet M; Osto E; Kratzer A; Stivala S; Kühnast S; Speer T; Doycheva P; Princen HM; van der Hoorn JW; Jukema JW; Giral H; Tailleux A; Landmesser U; Staels B; Lüscher TF
Atherosclerosis; 2017 Feb; 257():186-194. PubMed ID: 28152406
[TBL] [Abstract][Full Text] [Related]
6. Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.
Mohammadpour AH; Akhlaghi F
Clin Pharmacokinet; 2013 Aug; 52(8):615-26. PubMed ID: 23658137
[TBL] [Abstract][Full Text] [Related]
7. No cardiovascular benefit with evacetrapib - is this the end of the road for the 'cetrapibs'?
Doggrell SA
Expert Opin Pharmacother; 2017 Oct; 18(14):1439-1442. PubMed ID: 28799819
[TBL] [Abstract][Full Text] [Related]
8. On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors.
Johns DG; Duffy J; Fisher T; Hubbard BK; Forrest MJ
Drugs; 2012 Mar; 72(4):491-507. PubMed ID: 22356288
[TBL] [Abstract][Full Text] [Related]
9. Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With Evacetrapib.
Nicholls SJ; Ruotolo G; Brewer HB; Kane JP; Wang MD; Krueger KA; Adelman SJ; Nissen SE; Rader DJ
J Am Coll Cardiol; 2015 Nov; 66(20):2201-2210. PubMed ID: 26564598
[TBL] [Abstract][Full Text] [Related]
10. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies.
Krishna R; Anderson MS; Bergman AJ; Jin B; Fallon M; Cote J; Rosko K; Chavez-Eng C; Lutz R; Bloomfield DM; Gutierrez M; Doherty J; Bieberdorf F; Chodakewitz J; Gottesdiener KM; Wagner JA
Lancet; 2007 Dec; 370(9603):1907-14. PubMed ID: 18068514
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological Inhibition of CETP (Cholesteryl Ester Transfer Protein) Increases HDL (High-Density Lipoprotein) That Contains ApoC3 and Other HDL Subspecies Associated With Higher Risk of Coronary Heart Disease.
Furtado JD; Ruotolo G; Nicholls SJ; Dullea R; Carvajal-Gonzalez S; Sacks FM
Arterioscler Thromb Vasc Biol; 2022 Feb; 42(2):227-237. PubMed ID: 34937388
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of the Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib in Combination With Atorvastatin in Japanese Patients With Primary Hypercholesterolemia.
Teramoto T; Kiyosue A; Iimura T; Takita Y; Riesmeyer JS; Murakami M
Circ J; 2017 Dec; 82(1):183-191. PubMed ID: 28768921
[TBL] [Abstract][Full Text] [Related]
13. Cholesteryl ester transfer protein: An enigmatic pharmacology - Antagonists and agonists.
Yamashita S; Ruscica M; Macchi C; Corsini A; Matsuzawa Y; Sirtori CR
Atherosclerosis; 2018 Nov; 278():286-298. PubMed ID: 30347344
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Evacetrapib for Modifying Plasma Lipids: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Sahebkar A; Simental-Mendía LE; Guerrero-Romero F; Golledge J; Watts GF
Curr Pharm Des; 2016; 22(5):595-608. PubMed ID: 26601964
[TBL] [Abstract][Full Text] [Related]
15. Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease.
Lincoff AM; Nicholls SJ; Riesmeyer JS; Barter PJ; Brewer HB; Fox KAA; Gibson CM; Granger C; Menon V; Montalescot G; Rader D; Tall AR; McErlean E; Wolski K; Ruotolo G; Vangerow B; Weerakkody G; Goodman SG; Conde D; McGuire DK; Nicolau JC; Leiva-Pons JL; Pesant Y; Li W; Kandath D; Kouz S; Tahirkheli N; Mason D; Nissen SE;
N Engl J Med; 2017 May; 376(20):1933-1942. PubMed ID: 28514624
[TBL] [Abstract][Full Text] [Related]
16. Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.
Ford J; Lawson M; Fowler D; Maruyama N; Mito S; Tomiyasu K; Kinoshita S; Suzuki C; Kawaguchi A; Round P; Boyce M; Warrington S; Weber W; van Deventer S; Kastelein JJ
Br J Clin Pharmacol; 2014 Sep; 78(3):498-508. PubMed ID: 24628035
[TBL] [Abstract][Full Text] [Related]
17. Increased catabolic rate of low density lipoproteins in humans with cholesteryl ester transfer protein deficiency.
Ikewaki K; Nishiwaki M; Sakamoto T; Ishikawa T; Fairwell T; Zech LA; Nagano M; Nakamura H; Brewer HB; Rader DJ
J Clin Invest; 1995 Sep; 96(3):1573-81. PubMed ID: 7657828
[TBL] [Abstract][Full Text] [Related]
18. Effect of CETP inhibition with evacetrapib in patients with diabetes mellitus enrolled in the ACCELERATE trial.
Menon V; Kumar A; Patel DR; St John J; Riesmeyer J; Weerakkody G; Ruotolo G; Wolski KE; McErlean E; Cremer PC; Nicholls SJ; Lincoff AM; Nissen SE
BMJ Open Diabetes Res Care; 2020 Mar; 8(1):. PubMed ID: 32179516
[TBL] [Abstract][Full Text] [Related]
19. Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer Protein.
Reyes-Soffer G; Millar JS; Ngai C; Jumes P; Coromilas E; Asztalos B; Johnson-Levonas AO; Wagner JA; Donovan DS; Karmally W; Ramakrishnan R; Holleran S; Thomas T; Dunbar RL; deGoma EM; Rafeek H; Baer AL; Liu Y; Lassman ME; Gutstein DE; Rader DJ; Ginsberg HN
Arterioscler Thromb Vasc Biol; 2016 May; 36(5):994-1002. PubMed ID: 26966279
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib Administered as Monotherapy in Japanese Patients With Primary Hypercholesterolemia.
Teramoto T; Kiyosue A; Iimura T; Takita Y; Riesmeyer JS; Murakami M
Circ J; 2017 Oct; 81(11):1686-1692. PubMed ID: 28652529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
